LENZ
LENZ Therapeutics, Inc.
$4.81
+0.03
(+0.63%)
Mkt Cap
150.81M
Volume
439,221
52W Range
4.535-50.4
Sector
Healthcare
Beta
1.63
EPS (TTM)
-4.09 USD
P/E Ratio
-5.61
Revenue (TTM)
21.48M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 19.09M | 0 | 0 | 15.00M | 0 | 0 | 0 |
| Net Income | (82.13M) | (49.77M) | (69.97M) | (10.81M) | (70.76M) | (68.37M) | (109,000) |
| EPS | -2.85 | -2.34 | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Free Cash Flow | (70.00M) | (59.86M) | (60.41M) | (94.57M) | (58.59M) | (10.27M) | (19,000) |
| FCF / Share | -2.43 | -2.81 | -7.42 | -12.06 | -7.07 | -1.24 | -0.00 |
| Operating CF | (69.17M) | (59.39M) | (60.38M) | (87.98M) | (52.85M) | (8.72M) | (19,000) |
| Total Assets | 305.88M | 215.30M | 70.38M | 46.95M | 18.34M | 22.56M | 6,000 |
| Total Debt | 815,000 | 1.38M | 329,000 | 250,000 | 0 | 0 | 2.21M |
| Cash & Equiv | 25.18M | 20.16M | 35.14M | 44.44M | 18.31M | 19.82M | 6,000 |
| Book Value | 284.34M | 204.08M | (92.71M) | (24.17M) | (14.21M) | (9.80M) | (2.22M) |
| Return on Equity | -0.29 | -0.24 | N/A | N/A | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 1.90M | 1.59M | 12.50M | 5.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (31.92M) | (41.49M) | (35.90M) | (16.70M) | (14.91M) | (14.62M) | (12.65M) | (10.21M) | (10.25M) | (16.65M) | (23.69M) | (18.88M) |
| EPS | -1.02 | -1.32 | -1.16 | -0.59 | -0.53 | -0.53 | -0.46 | -0.38 | -0.40 | -3.53 | -2.77 | -2.75 |
| Free Cash Flow | (38.73M) | (33.60M) | (33.06M) | (9.03M) | (11.75M) | (16.16M) | (9.23M) | (10.77M) | (15.93M) | (23.94M) | (20.97M) | (13.09M) |
| FCF / Share | -1.23 | -1.07 | -1.06 | -0.32 | -0.42 | -0.59 | -0.34 | -0.40 | -0.62 | -5.07 | -2.53 | -1.60 |
| Operating CF | (38.71M) | (33.58M) | (33.02M) | (8.59M) | (11.51M) | (16.05M) | (9.08M) | (10.58M) | (15.79M) | (23.94M) | (20.97M) | (13.09M) |
| Total Assets | 236.60M | 272.54M | 305.88M | 210.70M | 217.33M | 201.25M | 215.30M | 224.01M | 202.64M | 217.32M | 70.38M | 92.17M |
| Total Debt | 122,000 | 673,000 | 815,000 | 954,000 | 1.05M | 1.18M | 1.38M | 1.58M | 1.70M | 589,000 | 329,000 | 360,000 |
| Cash & Equiv | 24.21M | 24.77M | 25.18M | 25.40M | 37.61M | 23.04M | 20.16M | 41.05M | 84.03M | 200.36M | 35.14M | 42.85M |
| Book Value | 219.26M | 246.49M | 284.34M | 193.93M | 206.37M | 192.01M | 204.08M | 215.28M | 192.92M | 198.17M | (92.71M) | (69.57M) |
| Return on Equity | -0.15 | -0.17 | -0.13 | -0.09 | -0.07 | -0.08 | -0.06 | -0.05 | -0.05 | -0.08 | N/A | N/A |
LENZ News
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China